Proteomic-biostatistic integrated approach for finding the underlying molecular determinants of hypertension in human plasma

Despite advancements in lowering blood pressure, the best approach to lower it remains controversial because of the lack of information on the molecular basis of hypertension. We, therefore, performed plasma proteomics of plasma from patients with hypertension to identify molecular determinants detectable in these subjects but not in controls and vice versa. Plasma samples from hypertensive subjects (cases; n=118) and controls (n=85) from the InGenious HyperCare cohort were used for this study and performed mass spectrometric analysis. Using biostatistical methods, plasma peptides specific for hypertension were identified, and a model was developed using least absolute shrinkage and selection operator logistic regression. The underlying peptides were identified and sequenced off-line using matrix-assisted laser desorption ionization orbitrap mass spectrometry. By comparison of the molecular composition of the plasma samples, 27 molecular determinants were identified differently expressed in cases from controls. Seventy percent of the molecular determinants selected were found to occur less likely in hypertensive patients. In cross-validation, the overall R(2) was 0.434, and the area under the curve was 0.891 with 95% confidence interval 0.8482 to 0.9349, P<0.0001. The mean values of the cross-validated proteomic score of normotensive and hypertensive patients were found to be -2.007±0.3568 and 3.383±0.2643, respectively, P<0.0001. The molecular determinants were successfully identified, and the proteomic model developed shows an excellent discriminatory ability between hypertensives and normotensives. The identified molecular determinants may be the starting point for further studies to clarify the molecular causes of hypertension

A Database of Anechoic Microphone Array Measurements of Musical Instruments

A collection of 3305 single notes of 41 musical instruments of different historical periods was recorded and analyzed. The database includes the instrument recordings, radiation patterns (directivities), and audio features such as the sound power or spectral centroid along with information about the identity and the making of the instrument and its player. The database can be used in virtual reality applications such as room acoustic simulation and auralization, or for the study of musical instruments acoustics themselves

Large-Scale Numerical Evidence for Bose Condensation in the S=1 Antiferromagnetic Chain in a Strong Field

Using the recently proposed density matrix renormalization group technique we show that the magnons in the S=1 antiferromagnetic Heisenberg chain effectively behaves as bosons that condense at a critical field h_c.Comment: 12 pages, REVTEX 3.0, 3 postscript figures appended, UBCTP-93-00

S(k) for Haldane Gap Antiferromagnets: Large-scale Numerical Results vs. Field Theory and Experiment

The structure function, S(k), for the s=1, Haldane gap antiferromagnetic chain, is measured accurately using the recent density matrix renormalization group method, with chain-length 100. Excellent agreement with the nonlinear $\sigma$ model prediction is obtained, both at $k\approx \pi$ where a single magnon process dominates and at $k\approx 0$ where a two magnon process dominates. We repeat our calculation with crystal field anisotropy chosen to model NENP, obtaining good agreement with both field theory predictions and recent experiments. Correlation lengths, gaps and velocities are determined for both polarizations.Comment: 11 pages, 3 postscript figures included, REVTEX 3.0, UBCTP-93-02

Impurities in s=1s=1 Heisenberg Antiferromagnets

The $s=1$ Heisenberg Antiferromagnet is studied in the presence of two kinds of local impurities. First, a perturbed antiferromagnetic bond with $J'\ne J$ at the center of an even-length open chain is considered. Using the density matrix renormalization group method we find that, for sufficiently strong or weak $J'$, a bound state is localized at the impurity site, giving rise to an energy level in the Haldane gap. The energy of the bound state is in agreement with perturbative results, based on $s=1/2$ chain-end excitations, both in the weak and strong coupling limit. In a region around the uniform limit, $J'=J$, no states are found with energy below the Haldane gap. Secondly, a $s=1/2$ impurity at the center of an otherwise even-length open chain is considered. The coupling to the $s=1/2$ impurity is varied. Bound states in the Haldane gap are found {\it only} for sufficiently weak (antiferromagnetic) coupling. For a $s=1/2$ impurity coupled with a strong (antiferromagnetic) bond, {\it no} states are found in the Haldane. Our results are in good qualitative agreement with recent experiments on doped NENP and Y$_2$BaNiO$_5$.Comment: 29 pages, RevTeX 3.0, 12 uuencoded postscript figures include

Equal Time Correlations in Haldane Gap Antiferromagnets

The $S=1$ antiferromagnetic Heisenberg chain both with and without single ion anisotropy is studied. Using the recently proposed density matrix renormalization group technique we calculate the energy gaps as well as several different correlation functions. The two gaps, $\Delta_{||}, \Delta_\perp$, along with associated correlation lengths and velocities are determined. The numerical results are shown to be in good agreement with theoretical predictions derived from the nonlinear sigma model and a free boson model. We also study the $S=1/2$ excitations that occur at the ends of open chains; in particular we study the behavior associated with open boundary conditions, using a model of $S=1/2$ spins coupled to the free bosons.Comment: 32 pages, uufiles encoded REVTEX 3.0, 19 postscript figures included, UBCTP-93-02

Large-scale genome-wide association studies and meta-analyses of longitudinal change in adult lung function.

BACKGROUND: Genome-wide association studies (GWAS) have identified numerous loci influencing cross-sectional lung function, but less is known about genes influencing longitudinal change in lung function. METHODS: We performed GWAS of the rate of change in forced expiratory volume in the first second (FEV1) in 14 longitudinal, population-based cohort studies comprising 27,249 adults of European ancestry using linear mixed effects model and combined cohort-specific results using fixed effect meta-analysis to identify novel genetic loci associated with longitudinal change in lung function. Gene expression analyses were subsequently performed for identified genetic loci. As a secondary aim, we estimated the mean rate of decline in FEV1 by smoking pattern, irrespective of genotypes, across these 14 studies using meta-analysis. RESULTS: The overall meta-analysis produced suggestive evidence for association at the novel IL16/STARD5/TMC3 locus on chromosome 15 (P  =  5.71 × 10(-7)). In addition, meta-analysis using the five cohorts with ≥3 FEV1 measurements per participant identified the novel ME3 locus on chromosome 11 (P  =  2.18 × 10(-8)) at genome-wide significance. Neither locus was associated with FEV1 decline in two additional cohort studies. We confirmed gene expression of IL16, STARD5, and ME3 in multiple lung tissues. Publicly available microarray data confirmed differential expression of all three genes in lung samples from COPD patients compared with controls. Irrespective of genotypes, the combined estimate for FEV1 decline was 26.9, 29.2 and 35.7 mL/year in never, former, and persistent smokers, respectively. CONCLUSIONS: In this large-scale GWAS, we identified two novel genetic loci in association with the rate of change in FEV1 that harbor candidate genes with biologically plausible functional links to lung function

Peripheral electrical stimulation in Alzheimer's Disease: A randomized controlled trial on cognition and behavior

In a number of studies, peripheral electrical nerve stimulation has been applied to Alzheimer's disease (AD) patients who lived in a nursing home. Improvements were observed in memory, verbal fluency, affective behavior, activities of daily living and on the rest-activity rhythm and pupillary light reflex. The aim of the present, randomized, placebo-controlled, parallel-group clinical trial was to examine the effects of electrical stimulation on cognition and behavior in AD patients who still live at home. Repeated measures analyses of variance revealed no effects of the intervention in the verum group (n = 32) compared with the placebo group (n = 30) on any of the cognitive and behavioral outcome measures. However, the majority of the patients and the caregivers evaluated the treatment procedure positively, and applying the daily treatment at home caused minimal burden. The lack of treatment effects calls for reconsideration of electrical stimulation as a symptomatic treatment in A

Extracellular Myocardial Volume in Patients With Aortic Stenosis

BACKGROUND: Myocardial fibrosis is a key mechanism of left ventricular decompensation in aortic stenosis and can be quantified using cardiovascular magnetic resonance (CMR) measures such as extracellular volume fraction (ECV%). Outcomes following aortic valve intervention may be linked to the presence and extent of myocardial fibrosis. OBJECTIVES: This study sought to determine associations between ECV% and markers of left ventricular decompensation and post-intervention clinical outcomes. METHODS: Patients with severe aortic stenosis underwent CMR, including ECV% quantification using modified Look-Locker inversion recovery-based T1 mapping and late gadolinium enhancement before aortic valve intervention. A central core laboratory quantified CMR parameters. RESULTS: Four-hundred forty patients (age 70 ± 10 years, 59% male) from 10 international centers underwent CMR a median of 15 days (IQR: 4 to 58 days) before aortic valve intervention. ECV% did not vary by scanner manufacturer, magnetic field strength, or T1 mapping sequence (all p > 0.20). ECV% correlated with markers of left ventricular decompensation including left ventricular mass, left atrial volume, New York Heart Association functional class III/IV, late gadolinium enhancement, and lower left ventricular ejection fraction (p < 0.05 for all), the latter 2 associations being independent of all other clinical variables (p = 0.035 and p < 0.001). After a median of 3.8 years (IQR: 2.8 to 4.6 years) of follow-up, 52 patients had died, 14 from adjudicated cardiovascular causes. A progressive increase in all-cause mortality was seen across tertiles of ECV% (17.3, 31.6, and 52.7 deaths per 1,000 patient-years; log-rank test; p = 0.009). Not only was ECV% associated with cardiovascular mortality (p = 0.003), but it was also independently associated with all-cause mortality following adjustment for age, sex, ejection fraction, and late gadolinium enhancement (hazard ratio per percent increase in ECV%: 1.10; 95% confidence interval [1.02 to 1.19]; p = 0.013). CONCLUSIONS: In patients with severe aortic stenosis scheduled for aortic valve intervention, an increased ECV% is a measure of left ventricular decompensation and a powerful independent predictor of mortality